Immune Activation and Collateral Damage in AIDS Pathogenesis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2013 Oct 18

PMID 24133492

Citations 43

Authors

Frank Miedema

Mette D Hazenberg

Kiki Tesselaar

Debbie van Baarle

Rob J De Boer

Jose A M Borghans

Affiliations

Soon will be listed here.

Abstract

In the past decade, evidence has accumulated that human immunodeficiency virus (HIV)-induced chronic immune activation drives progression to AIDS. Studies among different monkey species have shown that the difference between pathological and non-pathological infection is determined by the response of the immune system to the virus, rather than its cytopathicity. Here we review the current understanding of the various mechanisms driving chronic immune activation in HIV infection, the cell types involved, its effects on HIV-specific immunity, and how persistent inflammation may cause AIDS and the wide spectrum of non-AIDS related pathology. We argue that therapeutic relief of inflammation may be beneficial to delay HIV-disease progression and to reduce non-AIDS related pathological side effects of HIV-induced chronic immune stimulation.

Citing Articles

Regulatory T cells modulate monocyte functions in immunocompetent antiretroviral therapy naive HIV-1 infected people.

Georgia A, Claudine N, Carole S, Loveline N, Abel L, Flaurent T BMC Immunol. 2024; 25(1):68.

PMID: 39402453 PMC: 11472541. DOI: 10.1186/s12865-024-00654-8.

Intact provirus and integration sites analysis in acute HIV-1 infection and changes after one year of early antiviral therapy.

Rozera G, Sberna G, Berno G, Gruber C, Giombini E, Spezia P J Virus Erad. 2022; 8(4):100306.

PMID: 36582472 PMC: 9792883. DOI: 10.1016/j.jve.2022.100306.

Cardiovascular Implications of Immune Disorders in Women.

Moran C, Collins L, Beydoun N, Mehta P, Fatade Y, Isiadinso I Circ Res. 2022; 130(4):593-610.

PMID: 35175848 PMC: 8869407. DOI: 10.1161/CIRCRESAHA.121.319877.

A Real-world Evidence-based Management of HIV by Differential Duration HAART Treatment and its Association with Incidence of Oral Lesions.

Shu W, Du F, Bai J, Yin L, Duan K, Li C Curr HIV Res. 2021; 20(1):91-99.

PMID: 34961450 PMC: 9127730. DOI: 10.2174/1570162X20666211227154558.

Differential recognition of HIV-stimulated IL-1β and IL-18 secretion through NLR and NAIP signalling in monocyte-derived macrophages.

Triantafilou K, Ward C, Czubala M, Ferris R, Koppe E, Haffner C PLoS Pathog. 2021; 17(4):e1009417.

PMID: 33861800 PMC: 8109768. DOI: 10.1371/journal.ppat.1009417.

References

Cohen Stuart J, Hazebergh M, Hamann D, Otto S, Borleffs J, Miedema F . The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J Acquir Immune Defic Syndr. 2000; 25(3):203-11. DOI: 10.1097/00126334-200011010-00001. View

Lane H, Depper J, Greene W, Whalen G, Waldmann T, Fauci A . Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med. 1985; 313(2):79-84. DOI: 10.1056/NEJM198507113130204. View

Brenchley J, Price D, Schacker T, Asher T, Silvestri G, Rao S . Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365-71. DOI: 10.1038/nm1511. View

Levy Y, Durier C, Lascaux A, Meiffredy V, Gahery-Segard H, Goujard C . Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS. 2006; 20(3):405-13. DOI: 10.1097/01.aids.0000206504.09159.d3. View

Raffatellu M, Santos R, Verhoeven D, George M, Wilson R, Winter S . Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med. 2008; 14(4):421-8. PMC: 2901863. DOI: 10.1038/nm1743. View

Yonkers N, Sieg S, Rodriguez B, Anthony D . Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection. J Infect Dis. 2011; 203(5):635-45. PMC: 3072735. DOI: 10.1093/infdis/jiq101. View

Bucy R, Hockett R, Derdeyn C, Saag M, Squires K, Sillers M . Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest. 1999; 103(10):1391-8. PMC: 408455. DOI: 10.1172/JCI5863. View

Borghans J, Molgaard A, De Boer R, Kesmir C . HLA alleles associated with slow progression to AIDS truly prefer to present HIV-1 p24. PLoS One. 2007; 2(9):e920. PMC: 1976389. DOI: 10.1371/journal.pone.0000920. View

Moreland L, Curtis J . Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. Semin Arthritis Rheum. 2008; 39(2):132-43. DOI: 10.1016/j.semarthrit.2008.08.003. View

10.

Dahirel V, Shekhar K, Pereyra F, Miura T, Artyomov M, Talsania S . Coordinate linkage of HIV evolution reveals regions of immunological vulnerability. Proc Natl Acad Sci U S A. 2011; 108(28):11530-5. PMC: 3136285. DOI: 10.1073/pnas.1105315108. View

11.

Chang J, Lindsay R, Kulkarni S, Lifson J, Carrington M, Altfeld M . Polymorphisms in interferon regulatory factor 7 reduce interferon-α responses of plasmacytoid dendritic cells to HIV-1. AIDS. 2011; 25(5):715-7. PMC: 3098498. DOI: 10.1097/QAD.0b013e328343c186. View

12.

Friis-Moller N, Reiss P, Sabin C, Weber R, Monforte A, El-Sadr W . Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007; 356(17):1723-35. DOI: 10.1056/NEJMoa062744. View

13.

Gringeri A, Musicco M, Hermans P, Bentwich Z, Cusini M, Bergamasco A . Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study). J Acquir Immune Defic Syndr Hum Retrovirol. 1999; 20(4):358-70. DOI: 10.1097/00042560-199904010-00006. View

14.

Autran B, Murphy R, Costagliola D, Tubiana R, Clotet B, Gatell J . Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS. 2008; 22(11):1313-22. DOI: 10.1097/QAD.0b013e3282fdce94. View

15.

Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, Vardas E . Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol. 2004; 78(7):3233-43. PMC: 371059. DOI: 10.1128/jvi.78.7.3233-3243.2004. View

16.

Lempicki R, Kovacs J, Baseler M, Adelsberger J, Dewar R, Natarajan V . Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. Proc Natl Acad Sci U S A. 2000; 97(25):13778-83. PMC: 17652. DOI: 10.1073/pnas.250472097. View

17.

Picker L, Hagen S, Lum R, Reed-Inderbitzin E, Daly L, Sylwester A . Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection. J Exp Med. 2004; 200(10):1299-314. PMC: 2211921. DOI: 10.1084/jem.20041049. View

18.

Alter G, Suscovich T, Teigen N, Meier A, Streeck H, Brander C . Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J Immunol. 2007; 178(12):7658-66. DOI: 10.4049/jimmunol.178.12.7658. View

19.

Hsue P, Hunt P, Schnell A, Kalapus S, Hoh R, Ganz P . Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009; 23(9):1059-67. PMC: 2691772. DOI: 10.1097/QAD.0b013e32832b514b. View

20.

Meyaard L, Otto S, Jonker R, Mijnster M, Keet R, Miedema F . Programmed death of T cells in HIV-1 infection. Science. 1992; 257(5067):217-9. DOI: 10.1126/science.1352911. View